COMPASS Pathways plc (CMPS): Operating Cash Flow
-$157.24M
Year ended 2025-12-31
-$161.14M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$157.24M | n/m | 2026-03-24, From 2025-01-01 |
| 2024-12-31 | -$119.19M | n/m | 2026-03-24, From 2024-01-01 |
| 2023-12-31 | -$97.38M | n/m | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | -$105.45M | n/m | 2024-02-29, From 2022-01-01 |
| 2021-12-31 | -$67.75M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$41.38M | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$17.81M | n/a | 2022-02-24, From 2019-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | 2025-12-31 | -$157.24M | n/m |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $41.80M | +7.4% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $43.47M | -10.8% |
| Abeona Therapeutics Inc. (ABEO) | 2025-12-31 | -$76.33M | n/m |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$162.44M | n/m |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | -$86.10M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$76.44M | n/m |
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | -$128.34M | n/m |
| Evolus, Inc. (EOLS) | 2025-12-31 | -$42.27M | n/m |
Compare CMPS, PBYI, SIGA, ABEO side by side · Screen every company in Pharmaceutical Preparations ↗